Key result
This review evaluates the major predictors of stent thrombosis and the comparative efficacy and safety of ticagrelor versus clopidogrel in patients with acute coronary syndrome following intervention.
Why the study?
Does ticagrelor compared to clopidogrel reduce stent thrombosis in patients with acute coronary syndrome following transcutaneous coronary interventions?
Does ticagrelor compared to clopidogrel reduce stent thrombosis in patients with acute coronary syndrome following transcutaneous coronary interventions?
Answers are grounded in this paper and cite their sources.
This review evaluates the predictors of stent thrombosis and compares the efficacy and safety of ticagrelor versus clopidogrel in ACS patients post-PCI.
The review analyzes the reports addressing from different standpoints the issue of stent thrombosis and its major predictors in patients with acute coronary syndrome following transcutaneous coronary interventions. The review focuses on comparative efficacy and safety of ticagrelor and clopidogrel and the effect of double antiplatelet therapy on stent thrombosis. The issue of patients' compliance with double antiplatelet therapy is also discussed. Such comprehensive evaluation is warranted since despite all efforts for expanding both technical and therapeutic possibilities, the issue of stent thrombosis remains relevant.
No takes yet. Share an insight, caveat, or question.
Korotaeva et al. (2018) conducted a review in Acute coronary syndrome following transcutaneous coronary intervention. Ticagrelor and clopidogrel was evaluated on Stent thrombosis. This review evaluates the major predictors of stent thrombosis and the comparative efficacy and safety of ticagrelor versus clopidogrel in patients with acute coronary syndrome following intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: